H epatocellular carcinoma (HCC) is the most relevant form of liver cancer and the second most deadly cancer globally. This disease develops most commonly in individuals with sustained liver fibrosis or cirrhosis, following chronic inf lammation of the liver.
(1) The development of fibrosis involves the deposition of high levels of extracellular matrix (ECM) proteins and increased tissue tension, which together produce a stiff desmoplasia that promotes progression to cirrhosis. (2) Nonalcoholic fatty liver disease (NAFLD), a growing worldwide epidemic, (3) also involves liver fibrosis in a large number of cases. (4) The role of fibrosis in the early and late stages of liver diseases highlights the urgent need to find therapies that target this desmoplastic reaction.
Hepatic stellate cells (HSCs) are perisinusoidal cells, residing in the liver, (5) with roles in retinoid storage and force-mediated maintenance of the extracellular matrix. (6) In HCC, HSCs transition from a quiescent to a contractile activated state, and promote tumor development through production of a fibrotic stroma. (7) HSCs also engage in crosstalk with cancer cells in positive feedback loops that maintain the activated phenotype of HSCs as well as promote the growth of cancer cells. (8) Furthermore, the elevated deposition of fibronectin from activated HSCs drives the formation of the premetastatic niche that precedes liver colonization by pancreatic ductal adenocarcinoma (PDAC) cells. (9) HSCs are generated in the bone marrow along with pancreatic stellate cells (PSCs), (10) and share many equivalent functions with PSCs, such as storage of vitamin A droplets and ECM homeostasis. When activated, both cell types lose their vitamin A droplets and show high levels of stromal remodeling through their contractile myofibroblast-like phenotype. (11, 12) Cancer associated fibroblasts (CAFs), like activated HSCs and PSCs, are myofibroblast-like cells and correspondingly drive tumor progression through restructuring of the tumor microenvironment. (13) The similarity between these cell types highlights the importance of cell mechanics in tumor malignancy, and suggests that targeting the mechanical phenotype of these cells would be pertinent.
Activated HSCs, activated PSCs, and CAFs perpetuate fibrosis and a tumor-permissive microenvironment through multiple positive feedback loops that increase the active population of these cells. The actomyosin-dependent mechanical loop remodels and stiffens the ECM to a fibrotic state, and then responds to external rigidity by increasing cell contractility though myosin light chain 2 (MLC-2) regulation and inducing pro-fibrotic signaling pathways. (6, (12) (13) (14) In addition, HSCs have been shown to infiltrate into the tumor stroma and localize around the cancer cells, facilitating paracrine signaling. (15) Durotaxis, the process of directed migration based on substrate rigidity, has been observed in HSCs, and is suggested to lead to accumulation of HSCs and further potentiation of fibrosis as migrating HSCs become activated by the stiff environment. (16) The retinoic acid receptor family is known to modulate the function of HSCs, though the molecular mechanisms behind this regulation are not well understood. Elucidating the molecular events underlying HSC activation holds the key to blocking progression of early and advanced liver diseases. Here we show that expression of retinoic acid receptor beta (RAR-β) is significantly downregulated in patients with HCC and cirrhosis in comparison with healthy individuals. We observed that all trans-retinoic acid (ATRA) induces the RAR-β-mediated negative transcriptional regulation of MLC-2, and consequently reduces force generation and mechanosensing. These processes sustain the stiff microenvironment needed for the activated phenotype in HSCs. Furthermore, deactivated HSCs have an impaired ability to remodel artiCle iNForMatioN: the matrix and do not display directed migration toward stiffer substrates.
Materials and Methods

tissUe MiCroarrays
Tissue microarray (TMA) blocks were constructed as previously described (17) using 20 archival paraffin-embedded HCC tissue blocks and 10 healthy controls retrieved from the Imperial College London Tissue Bank (Ethical Approval nr. R15058). All experiments were performed in accordance with Imperial College guidelines and regulations. All experimental protocols have been approved by the Research Ethics Committee Wales approval 12/WA/0196, license number 12275. Written consent was obtained from all subjects. A consultant histopathologist reviewed all the materials prior to inclusion on freshly cut hematoxylin and eosin (H&E) slides. We constructed TMA blocks using an MTA-1 Microarrayer (Mitogen, United Kingdom) following H&E-slide guided microdissection of target tumor and surrounding nontumorous areas. We obtained triplicates of 1 mm cores from separate central and peripheral areas of tumor and matching surrounding liver. Adequate sampling of target tissues was confirmed on a freshly cut H&E section from the recipient TMA block before downstream analysis. For quantification of the levels of RAR-β, MLC-2, and phosphorylated MLC-2 (pMLC-2) in human liver tissues from healthy, cirrhosis, and HCC, the TMAs were obtained from Biomax (Catalog number: BC03117).
MUriNe FiBrosis MoDel
All research using live animals was approved by local ethics committees (Imperial College Central Animal Welfare Ethical Review Board) and was carried out under Home Office supervision in accordance with the European Directive 2010/63/ EU. All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985) Mice were housed in specific pathogen-free conditions in individually ventilated cages (Techniplast UK Ltd). The environment was controlled with a 12-hour light/dark cycle, ambient temperature of 21°C (+/-2°C), and humidity of 55% (+/-10%). Mice had access to irradiated diet (Special Diet Services UK) and water (25 ppm chlorine) ad libitum. Five male C57BL/6 mice, aged 8-12 weeks, were dosed twice weekly for 6 weeks with 0.4 μL/g CCl 4 diluted 1 in 3 in olive oil, administered via the intraperitoneal route. Three male age-and strainmatched cohoused "vehicle only" control mice were dosed to the same regimen with the same by-weight volume of olive oil. Mice were culled 72 hours following the last injection of CCl 4 . To validate the induction of fibrosis, Sirius Red staining was performed (by the Department of Pathology, St Mary's Hospital Imperial College London). The collagen proportionate area was calculated by quantification of the area of collagen (Sirius Red-stained tissue) as a proportion of the total tissue area using Image J. Eight representative fields at ×10 magnification were assessed for each mouse.
Cell CUltUre aND aNtiBoDies
Primary, culture-activated human HSCs, passage 3-6 (HHStec 5300; ScienCell, Carlsbad, CA), were cultured in phenol red medium (DMEM-F12 HAM; Sigma Aldrich, D6434) supplemented with 10% fetal bovine serum (Gibco, 10500-064), 1% penicillin/streptomycin (Sigma Aldrich, P4333), and 1% Fungizone R Amphotericin B (Gibco, 15290-026). HSCs were treated with 1 μM ATRA dissolved in absolute ethanol (Fisher, E/0650DF/17) for 10 days. Control HSCs were cultured with an equivalent amount of 0.1% ethanol in media as vehicle control. Medium for both control-and ATRA-treated HSCs was changed every 24 hours, and changing of media was performed in subdued light. Both control-and ATRA-treated HSCs were incubated with phenol red culture medium supplemented with 2% fetal bovine serum. HSCs were exposed to 1 μM of RAR-β agonist (cd2314, Tocris, 3824) for 72 hours. RAR-β antagonist (cd2665, Tocris, 3800) was used at 1 µM. All cells were tested for mycoplasma con- 
rt-pCr
Total RNA was extracted using the RNeasy Mini kit (Qiagen, 74104) and 1 µg of total RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA kit (Applied Biosystems, 4387406) according to the manufacturer's instructions. Real-time quantitative PCR (qPCR) was performed using the SYBR Green PCR Master Mix (Applied Biosystems, 4309155). Primer sequences: glyceraldehyde 3-phosphate dehydrogenase: forward-5′-ACAGTTGCCATGTAGACC-3′, reverse-5′-TTTTTGGTTGAGCACAGG-3′; RAR-β: forward 5'-AATAAAGTCACCAGGAATCG -3' and reverse, 5'-CAGATTCTTTGGACATTCCC -3'; MLC-2: forward, 5′-ATCCACCTCCATC T CTT-3′ and reverse, 5′-AATACACGACCTCCTGTT-3′.
iMMUNoFlUoresCeNCe staiNiNg
Cell immunofluorescence staining was done on coverslips coated with 10 μg mL −1 fibronectin (Gibco, phe0023). Following pertinent treatment, cells were fixed with 4% paraformaldehyde (Sigma, P6148) in Dulbecco's phosphate-buffered saline (D-PBS; Sigma, D8537) for 10 minutes, and then blocked and permeabilized with 0.2% bovine serum albumin, 0.1% Triton (Sigma, T8787) in phosphate-buffered saline (PBS) for 30 minutes. After blocking, cells were incubated with primary antibodies prepared in blocking solution overnight at 4 degrees in a humidified chamber. Then, cells were washed in D-PBS and incubated with Alexa Fluor 488-conjugated secondary antibodies and phalloidin (Invitrogen, A22283, 1/1,000 dilution) prepared in PBS for 1 hour at room temperature. Finally, coverslips were washed in PBS and mounted in mounting reagent with 4,6-diamidino-2-phenylindole (Invitrogen, P36931). Immunofluorescent images were taken with Nikon Ti-e Inverted Microscope (Nikon, Kingston-upon-Thames, United Kingdom) with NIS elements software.
CoMpUtatioNal aND BiopHysiCal MetHoDs
The methodology for traction forces, atomic force microscopy (AFM), mechanosensing, functional/ remodeling assay, and durotaxis followed previously reported procedures. (12, 16) A complete description can be found in Supporting methods information.
Results
rar-β is DeCreaseD iN CirrHotiC aND HCC HUMaN liVer tissUes
To investigate whether RAR-β is differentially expressed in hepatic tissues, we used tissue microarrays and immunofluorescence of human liver tissues from healthy individuals and patients with cirrhosis. Activated HSCs in vitro have been shown to have reduced expression of RAR-β compared with their quiescent state, (18) and HSCs isolated from cholestatic liver fibrosis also show a diminished RAR-β expression. (19) We identified activated HSCs and other myofibroblasts in the tissue section using positive staining of α-SMA, a widely accepted marker for activated HSCs. (5) We observed that RAR-β was abundantly expressed in healthy tissue, which was also characterized by very low or negligible abundance of activated HSCs. In cirrhotic liver, RAR-β was greatly reduced in areas where activated HSCs were present ( Fig. 1A ; Supporting Fig. S1 ), in concurrence with the known reduction of RAR-β expression in activated HSCs. (18) The overall expression of RAR-β across the tissue was 70% lower in cirrhotic tissue compared with healthy tissue (Fig. 1B) .
Solid tumors in multiple organs are characterized by a decrease in RAR-β expression. (20) We analyzed the gene expression of this receptor using samples of 371 patients with HCC and 50 healthy individuals from The Cancer Genome Atlas dataset and observed that the expression of RAR-β in patients with HCC was significantly lower than in normal samples (P = 7.11e-06) (Fig. 1C) . This trend correlates with our immunofluorescence results, which indicates that the loss of RAR-β expression occurs primarily in the activated HSC population, and reveals that like multiple other tumors, loss of RAR-β expression may be associated with malignancy in the liver.
atra iNDUCes tHe eXpressioN oF rar-β aND NegatiVely regUlates MlC-2 IN VITRO
ATRA is an active vitamin A metabolite and a known exclusive agonist of RARs, including RAR-β. (21) Vitamin A has been shown to positively regulate RAR-β expression in rat maternal tissues. (22) HSCs are known to express all isoforms of the RAR family (α, β, and γ), each of which are differentially responsive to various retinoids. (18) We treated HSCs with 1 µM ATRA for 10 days, a concentration and time comparable to those in previous studies on similar cells. (12, 23, 24) The mRNA expression of RAR-β was significantly increased in ATRA-treated HSCs compared with control (Fig. 1D) . RAR-β expression was also up-regulated at the protein level in HSCs after ATRA treatment ( Fig. 1E,F; Supporting Fig.  S2 ). Collectively, this indicates an increase in RAR-β expression at both the gene and protein levels in response to ATRA.
It has been observed that tissue tension promotes chronic HSC activation. (6, 25) Thus, we investigated whether RAR-β activation in HSCs affected the expression of myosin light chain-2 (MLC-2), a key regulatory protein in cytoskeletal contractility. (26) Using qPCR, we observed that treatment of HSCs with a RAR-β agonist (cd2314) for 72 hours induced a significant decrease in MLC-2 mRNA expression, a reduction also observed with the 10-day ATRA treatment. Combining ATRA treatment with a RAR-β antagonist (cd2665) prevented the effect of ATRA, with control levels of MLC-2 mRNA expression observed ( Fig. 2A) . This suggests that ATRA downregulates MLC-2 levels through RAR-β activation.
Immunofluorescence staining was also used to assess protein levels of MLC-2 and its phosphorylated active form, pMLC-2. Both ATRA treatment for 10 days and RAR-β agonist treatment for 72 hours were observed to reduce the protein levels of total MLC-2, and proportionally, levels of the active form of MLC-2 (pMLC-2) (Fig. 2B,C) . Compared with the control condition, ATRA + RAR-β antagonist treatment for 10 days, and RAR-β agonist treatment for 72 hours after RAR-β was knocked down using small interfering RNA (siRNA), did not show significantly different levels of expression of either MLC-2 or pMLC-2.
We also studied the effect of ATRA treatment for 72 hours on the MLC-2 and pMLC-2 levels of HSCs. We observed a significant inhibition in the levels of both MLC-2 and pMLC-2 using immunofluorescence and Western blot. ATRA exposure for 72 hours after HSCs were treated with siRNA against RAR-β did not show significantly different levels of expression of MLC-2 and pMLC-2 compared with control ( Supporting Fig. S3 ). Taken together, these results confirm the negative regulation of MLC-2 expression in HSCs via RAR-β.
MlC-2 is UpregUlateD iN CirrHosis aND HCC
In order to investigate further the relationship between RAR-β and MLC-2 in fibrosis, we assessed protein levels of RAR-β and MLC-2 in healthy and fibrotic mouse models. We used C57BL/6 mice, aged 8-12 weeks, and randomized them in two groups. One group was injected with CCl 4 (via intraperitoneal injection) for 6 weeks to induce fibrosis and the other was administered olive oil as vehicle control. CCl 4 -induced fibrosis is a well-validated model of murine fibrosis. (27) To validate the induction of fibrosis, Sirius Red staining was performed. The collagen proportionate areas increased around four times in tissues from CCl 4 treated mice compared with vehicle control (Supporting Fig. S4 ). We observed a significant reduction in the expression of RAR-β, and an overall 2-fold increase in MLC-2 expression in fibrotic tissues compared with vehicle control. We used α-SMA staining to identify HSCs (myofibroblast phenotype) and observed negligible levels of α-SMA in control tissues but substantial expression in fibrotic tissues, where the α-SMA-positive stained areas showed almost no expression of RAR-β. In stark contrast, MLC-2 staining colocalized with the α-SMA-positive stained areas in CCl 4 -treated fibrotic tissues. In control tissues, MLC-2 was expressed at very low levels and always in α-SMA-positive cells (Fig. 2D) .
We then used human tissues from healthy, cirrhotic, and HCC livers and quantified the levels of expression of RAR-β, MLC-2, and pMLC-2. Staining with α-SMA identified HSCs and other myofibroblast-like cells. In healthy tissues, we observed very little expression of α-SMA, but substantial expression of RAR-β, most likely in healthy hepatocytes. Cirrhotic and HCC tissues showed large α-SMA-positive areas that colocalized with MLC-2 and pMLC-2 but not with RAR-β expression (Fig. 3A) . Overall, the RAR-β expression was gradually and significantly decreased from healthy to cirrhotic to HCC tissues, whereas MLC-2 and pMLC-2 expression were upregulated 2-fold from healthy to HCC tissues (Fig. 3B) . Based on tumor-node-metastasis staging criteria (seventh edition), (28) we then classified the HCC specimens according to their T stage in two groups: T1/T2 (early stage) and T3/T4 (advanced stage). When we compared the T3/T4 against the T1/ T2 group, we found a 20% decrease in RAR-β expression associated with a stage-dependent 30% increase in MLC-2 levels (Fig. 3C) .
In order to conduct functional experiments in a physiological relevant system, we cultured HSCs on 12 kPa polyacrylamide gels, fabricated using a previously reported protocol. (16) The use of these gels recapitulates a biomechanical environment close to fibrotic liver tissue. (29) RAR-β was expressed in control HSCs at a modest level, but the expression increased by 50% following ATRA treatment for 72 hours. Notably, RAR-β showed a very high nuclear localization in ATRA-treated HSCs compared with control HSCs. ATRA treatment significantly decreased MLC-2 levels in HSCs, but the levels comparable to control HSCs were observed following ATRA treatment in the presence of siRNA against RAR-β (Fig. 3D,E) . Taken together, these results indicate that MLC-2 and pMLC-2 are up-regulated in cirrhotic and HCC tissues and strongly suggest that ATRA treatment negatively regulates MLC-2 via RAR-β in vivo.
atra iNHiBits ForCe geNeratioN aND MeCHaNoseNsiNg iN HsCs
Cytoskeletal rearrangement and increased actomyosin contractility are required for the maintenance of the activated phenotype in HSCs. (30) Myofibroblasts, which bear phenotypic resemblance to activated HSCs, also require high cytoskeletal contractility for their function. (12) This highly mechanoresponsive and contractile phenotype of HSCs is adaptive in a wound-healing context but can promote fibrosis in a disease context. (25) We used elastic pillars to assess the effect of ATRA treatment on force generation in HSCs. Polydimethylsiloxane pillars were coated with fibronectin to facilitate cell attachment and the deflection of each pillar was monitored during the process of cell spreading. The traction force per pillar was calculated using its deflection and the known Young's modulus of the pillar array. ATRA-treated HSCs (10 days) were observed to generate significantly reduced traction forces compared with control HSCs, but this inhibition was lost when ATRA was combined with RAR-β antagonist. Similarly, 72-hour RAR-β agonist treatment significantly reduced force generation, but the effect was rescued when the treatment was performed after siRNA-mediated knock down of RAR-β (Fig. 4A,B) . 72-hour ATRA treatment also led to significantly reduced force generation, whereas ATRA treatment combined with siRNA against RAR-β led to generation of forces similar to control (Supporting Fig. S5 ).
Cytoskeletal stiffness is associated with the rheological properties of cells and their ability to generate forces. (31, 32) HSC activation requires reorganization of the actin cytoskeleton, and cytoskeletal disrupting drugs, which are known to reduce the Young's modulus of cells, (33) inhibit the activated phenotype. (34) We used AFM indentation of individual cells to study HSC elasticity and observed a reduced Young's modulus in 10-day ATRA-treated HSCs (softer HSCs), implying a reduced cytoskeletal tension. This effect was reverted when ATRA was supplied simultaneously with the RAR-β antagonist. We also observed that RAR-β agonist (72-hour treatment) reduced the Young's modulus, but not after HSCs were treated with siRNA against RAR-β (Fig. 4C) . Similarly, ATRA treatment for 72 hours led to cell softening, but no difference to control was seen when the treatment followed transfection of HSCs using siRNA against RAR-β (Supporting Fig. S5 ).
The capacity of cells to apply forces on their substrates correlates with their ability to remodel the underlying matrix. (12) To further investigate the effect of ATRA on the ability of HSCs to remodel the ECM, we embedded Matrigel-collagen gels with HSCs and allowed them to contract the gels. 10-day ATRA-treated HSCs showed a significantly reduced capacity to contract the gels, comparable to treatment of HSCs with the myosin II ATPase inhibitor Y27632 (Fig. 4D) . Treatment of cells with both ATRA and Y27632 did not further reduce gel contraction, supporting the fact that ATRA exerts its effects through reduction of actomyosin contraction. Additionally, the ability to contract the gels was rescued by transfecting ATRA-treated HSCs with a plasmid to promote MLC-2 overexpression (Supporting Fig. S6 ).
Mechanosensing ECM rigidity also relies on cytoskeletal rearrangement and actomyosin contractility. (35) Mechanosensing was assessed using magnetic tweezers microrheology, in which fibronectin-coated magnetic beads are attached to the cell of interest via integrin receptors and undergo 12 consecutive pulses of equal force (Fig. 4E) . Mechanoresponsive cells reduce the amplitude of these pulses as force application to a localized cell area of integrins triggers an adaptive reinforcement, requiring cytoskeletal remodeling through the RhoA-ROCK-MLC-2 signaling axis. (35) Ostensibly, this behavior allows a cell to regulate its cytoskeletal stiffness in response to its mechanical environment. We observed that control HSCs responded to the external mechanical stimulus applied by the bead by showing a significant cytoskeletal stiffening, as the twelfth pulse was significantly smaller than the first pulse, whereas 10-day ATRAtreated cells did not show this significant reduction (Fig. 4F) . This reveals that ATRA treatment impairs the ability of HSCs to respond to external forces, i.e., mechanosensing.
atra iNDUCes MeCHaNiCal QUiesCeNCe iN HsCs
Force generation and mechanosensing of ECM rigidity are essential to promote the activated phenotype in myofibroblasts. (36) The activation of stellate cells is characterized by a lack of the cytoplasmic lipid droplets, which are present in the quiescent state, as well as increased expression of α-SMA and vimentin. (37) α-SMA contributes to mechanical tension within myofibroblasts, (32) and the intermediate filament component vimentin can mediate cytoskeletal organization and focal adhesion maturation. (38) Immunofluorescence staining of α-SMA and vimentin indicated higher levels of these proteins in control HSCs compared with 10-day ATRA-treated HSCs. The effect of ATRA was lost in the presence of the RAR-β antagonist. The treatment of HSCs with RAR-β agonist (72 hours) also decreased expression of α-SMA and vimentin, and this effect was not observed when the treatment was performed after transfecting HSCs with siRNA RAR-β (Fig. 5A,B) . ATRA treatment for 72 hours and ATRA + siRNA RAR-β also followed the same trend (Supporting Fig. S7 ). qPCR analysis of control HSCs and 10-day ATRA-treated HSCs confirmed the shift toward quiescence as mRNA expression of both α-SMA and vimentin was significantly reduced (Fig. 5C ). Oil Red O staining was performed to determine the presence of cytoplasmic lipid droplets. (37) We confirmed that control activated HSCs showed minimal staining with Oil Red O, significantly less than observed in ATRA-treated HSCs (Fig. 5D,E) . Together, these results suggest the consistent acquisition of a quiescent phenotype of HSCs following ATRA treatment.
atra treatMeNt reDUCes proDUCtioN oF eCM proteiNs
One of the hallmarks of fibrosis is the deposition of excess levels of ECM proteins, such as collagen and fibronectin. Activated HSCs, in their role as stroma-resident stellate cells, secrete both collagen and fibronectin at high levels. (2) The importance of fibronectin secretion in tumor microenvironments, and its transcriptional regulation in cancer, is substantiated by the specificity of alternatively spliced isoforms of fibronectin in different cancers. For example, liver cancer is associated with increased expression of the extra domain-A (EDA) spliced form of fibronectin, (39) which can promote HSC motility. (40) Another spliced form of fibronectin, extra domain-B (EDB), has been shown to promote fibroblast proliferation and deposition of fibronectin in mice. (41) Using qPCR, we observed that mRNA expression of fibronectin, fibronectin-EDA, fibronectin-EDB, and collagen I are significantly reduced following 10-day ATRA treatment (Fig. 6A) , indicating the role of ATRA in inhibiting ECM protein transcription. At the protein level, immunofluorescence staining showed a significant reduction in both intracellular and extracellular fibronectin and collagen I in response to 10-day ATRA treatment. The presence of the RAR-β antagonist during the 10-day ATRA treatment reverted fibronectin and collagen I values to those observed in control HSCs. RAR-β agonist also significantly reduced expression of these ECM proteins, with rescue observed in combination with siRNA RAR-β (Fig. 6B,C) . 72-hour ATRA treatment also reduced expression, with rescued expression when combined with siRNA RAR-β (Supporting Fig. S8 ). Collectively these results show that ATRA suppresses the transcription of collagen I and fibronectin, and their expression and secretion by HSCs.
atra iNHiBits DUrotaXis iN HsCs
We have previously reported that HSCs can perform rigidity gradient directed movement toward a stiffer substrate, also known as durotaxis. (16) We used a dual-rigidity gradient gel to determine whether ATRA can inhibit the ability of HSCs to exhibit durotaxis. The fibrotic microenvironment that facilitates tumor progression has increased rigidity compared with the rest of the stroma; therefore, durotaxis behavior in HSCs represents a further mechanical positive feedback loop by which HSCs accumulate in fibrotic areas and become activated to potentiate fibrosis.
We observed that control HSCs perform durotaxis as previously shown, traveling on average 73.5 µm toward the stiff substrate over 5.5 hours. Treatment of HSCs with either ATRA or the RAR-β agonist (cd2314) fully abrogated durotaxis behavior, with no observable migration along the stiffness gradient. Durotaxis can be rescued in ATRA-treated cells with overexpression of MLC-2 (average distance travelled = 59.5 µm), indicating that ATRA exerts its effect by inhibiting myosin activity (Fig. 7A,C;  Supporting videos 1-4) . Correspondingly, cell speed (in all directions) is also affected by RAR-β activation, with control HSCs travelling on average 0.89 µm per minute and RAR-β activation by ATRA and the RAR-β agonist significantly reducing this speed to 0.36 and 0.33 µm per minute, respectively. As with durotaxis, MLC-2 overexpression could rescue the cell speed of ATRA-treated cells to an average cell speed of 1.0 µm per minute, a value not significantly different from the control condition (Fig.  7B) . Together, this indicates the sensitivity of durotaxis and cell migration to RAR-β signaling, providing further evidence for the manifold effects of retinoid signaling in a variety of cell behaviors that can regulate cancer development through mechanical positive feedback loops.
Discussion
Retinoids, metabolites of vitamin A, have long been studied in cancer therapeutics because of their varied effects on cells, with one of the most successful examples shown in the treatment of promyelocytic leukemia. (42) There exists a close link between RAR-β expression and cancer, with loss of the RAR-β2 isoform occurring in breast, lung, esophagus, pancreas, cervix, and prostate tumors. (20) We report here that RAR-β expression is significantly reduced in both mouse models of fibrosis and human samples of cirrhosis and HCC. Interestingly, this loss of expression occurs in the tissue areas populated by HSCs. Therefore, our results corroborate the importance of RAR-β in cancer and suggest that RAR-β might be an attractive target to develop new therapies against HSCs to suppress the desmoplastic reaction associated with HCC and cirrhosis.
As the primary cell type that drives liver fibrosis, HSCs are an important target in (1) understanding the emergence and maintenance of fibrosis and (2) developing therapeutics to abrogate the tumor permissive microenvironment. (43) We show that MLC-2 expression in vivo increases with fibrosis, and also with the development of HCC through cirrhosis, and that RAR-β activation in our in vitro liver model, using liver specific substrate rigidity, down-regulates MLC-2 expression. Negative regulation of MLC-2 in vitro inhibits cytoskeletal tension, endogenous forces, mechanosensing, and ECM deposition, the key components of the signaling loop that initiates and maintains the myofibroblast-like phenotype. (18) Our results therefore reveal a previously unidentified mechanism to target mechanotransduction in HSCs by regulating MLC-2 transcription (Fig. 8) , and we suggest that mechanical reprogramming of HSCs through RAR-β may be a plausible option for several liver disorders.
Cancer cells can recruit HSCs through secretion of cytokines that guide the migration of HSCs through chemotaxis. (44) Mutually activating bidirectional crosstalk between hepatocytes and HSCs is known to promote a tumor-permissive microenvironment, and directed migration of HSCs to the tumor augments this crosstalk and HCC progression. (8) We have recently shown that durotaxis is another mechanism by which HSCs can be recruited to the fibrotic site, with directed migration via a stiffness gradient. (16) Furthermore, the stiff environment generated by activated HSCs can recruit yet more HSCs through durotaxis, leading to accumulation. (43) Durotaxis therefore represents a cellular process that underpins multiple positive feedback loops. Notably, we observe that ATRA inhibits HSC durotaxis through down-regulation of MLC-2 expression and subsequent mechanical deactivation, which implies that retinoid signaling can reduce intercell pro-oncogenic crosstalk, both between cancer cells and HSCs and within the wider HSC population.
The potential therapeutic value of mechanical deactivation of HSCs through the RAR-β/ MLC-2 axis is not limited to HCC, as stromal remodeling by HSCs and other myofibroblast-like cells is essential in the progression of other diseases with a wider impact on the worldwide population, such as NAFLD. In NAFLD mouse models, a synthetic agonist of RAR-β has been shown to deactivate HSCs, leading to reduced steatosis and oxidative stress in the liver. (45) It has been documented that fibrosis in NAFLD is reversible, (46) and our observation that RAR-β activation prevents stromal remodeling by HSCs, when viewed in conjunction with the previous studies on NAFLD mouse models, emphasizes the importance of retinoid signaling in HSCs and its wide-ranging therapeutic potential.
Furthermore, it is known that PDAC cells form metastases in the liver preceding formation of the primary tumor. (47) Colonizing PDAC cells require a premetastatic niche in the liver, with the activation of HSCs, and subsequent increased fibronectin deposition, indispensable for the formation of this niche. (9) Therefore, we propose that RAR-β may also be relevant for clinical intervention of PDAC metastasis in the liver.
In conclusion, our combined findings highlight RAR-β as a transcriptional regulator of cell biomechanics and microenvironmental remodeling in HSCs. The increasing but still emerging appreciation that mechanotransduction is fundamental in the biology of stromal cells such as HSCs should lead to innovative approaches in stromal reprogramming and reversal of several liver disorders.
